• br Conflict of interest statement br Benign prostatic

  2024-02-06

  

  Conflict of interest statement Benign prostatic hyperplasia (BPH) is a highly complex process characterized by an increased number of epithelial and stromal flumethasone mg in the transition zone. , , Autopsy studies by McNeal detail the evolution of histological changes within these 2 cellula

• For the NSCLC patients with EGFR activating mutations

  2024-02-06

  

  For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment

• Aurora B is also very important in proper cytokinesis

  2024-02-06

  

  Aurora-B is also very important in proper cytokinesis. In the absence of Aurora-B mediated phosphorylation of Ser72 in vimentin, the two daughter cells remain attached to each other through bridges of cytoplasm; cytokinesis fails [31]. Other Aurora-B dependent proteins that are important for cytokin

• Because ASK signaling in microglia

  2024-02-05

  

  Because ASK1 signaling in microglia and astrocytes is important during EAE, we hypothesized that a combination therapy that targets T cells along with microglia and astrocytes would further ameliorate the severity of EAE. We tested this hypothesis by applying valproic BPTES (VPA)—a short-chain fatt

• The mitochondrial protein AIF was the first caspase independ

  2024-02-05

  

  The mitochondrial protein AIF was the first caspase-independent death effector. AIF can induce caspase-independent chromatin condensation and large-scale DNA fragmentation to approximately 50 KB. AIF that is released to cytoplasm can mediate apoptosis when special extracellular signals trigger the o

• br Materials and methods br

  2024-02-05

  

  Materials and methods Results and discussion Conclusion Funding This work was supported by the Canadian Institute of Health Research (CIHR) [grant number FDN-148413] to PS, the National Science and Engineering Research Council of Canada (NSERC) [grant number CRD-399680] to ÉM, and the FR

• Plant pathogenic fungi have caused

  2024-02-05

  

  Plant pathogenic fungi have caused a lot of economic losses to agricultural production worldwide every year. It is necessary to develop an bio-sourced antifungal agent for agricultural use. Many researches have shown that the antifungal activity of quaternized chitosan derivatives is mainly affected

• Recently Kamoshita et al evaluated

  2024-02-05

  

  Recently, Kamoshita et al. (2016) evaluated a mouse model of retinal neuronal disturbance with the intraperitoneal injection of LPS and found that treatment with AICAR suppressed the reduction of conical function and decreased mRNA levels of TNF-α as well as improved mRNA levels of the mitochondrial

• It remains to elucidate whether proteolytic activity is the

  2024-02-05

  

  It remains to elucidate whether proteolytic activity is the cause or the consequence of changing levels of peptidergic substrates. In fact, in some cases, the expression of the enzyme does not necessarily parallel with its activity [26], [55], [57] and other factors such as a definite biochemical en

• Epidermal growth factor EGF has been shown

  2024-02-05

  

  Epidermal growth factor (EGF) has been shown to increase the 12S-lipoxygenase mRNA level by about two-fold in human epidermoid carcinoma A431 cells [71]. This enzyme was shown to be of the platelet-type and associated with the microsomal fraction of the cells [71], [72]. A requirement for EGF recept

• Through an extensive SAR optimization campaign with

  2024-02-05

  

  Through an extensive SAR optimization campaign with the 4-((2-hydroxy-3-methoxybenzyl)amino)-benzenesulfonamide-based scaffold researchers have developed ML355 ((N-benzo[d]thiazol-2-yl)-4((2-hydroxy-3 methoxybenzyl)amino)benzenesulfonamide) [5]. ML355 is a nonreductive, noncompetitive, reversible 12

• Imatinib was first approved for

  2024-02-05

  

  Imatinib was first approved for the treatment of Philadelphia chromosome positive chronic myelogenous leukemia in 2001 [25]. This first approved small molecule antagonist is quite unusual in that it provides a durable response that lasts for more than a decade in the majority of patients. Imatinib h

• br Perspectives and challenges Previously the main

  2024-02-05

  

  Perspectives and challenges Previously, the main focus of development of adenosine targets for pain was on A1Rs, due to prominent antinociception in multiple preclinical models and preliminary observations in human trials. However, delivery of agonists can be limited by other (e.g. cardiovascular

• br Materials and methods br Results Bilateral microinjection

  2024-02-04

  

  Materials and methods Results Bilateral microinjections (n = 6) of 10 mM ACh (300–500 pmol) and 5 mM physostigmine (150–250 pmol) at the two selected caudal NTS sites caused within 1 min significant increases in respiratory frequency (from 54.5 ± 1.7 to 70.9 ± 4.1 breaths/min; +30.8 ± 7.0%; P 

• The structures of these compounds were

  2024-02-04

  

  The structures of these compounds were confirmed from their spectral and micro analytical data. Based on [M + H] 367, molecular formula of was established as CHON. The IR spectrum of showed Octyl-α-ketoglutarate receptor due to CO stretching at 1700 Cm & OH stretching at 3188 Cm indicating that c

16105 records 174/1074 page Previous Next First page 上5页 171172173174175 下5页 Last page